title: A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
abstract: Patients with metastatic triple-negative breast cancer (mTNBC) typically have a poor prognosis. The purpose of this study was to prospectively evaluate the efficacy and toxicity of biweekly combination of vinorelbine and oxaliplatin (NVBOX) in second- or third-line setting for mTNBC. Eligible patients were female with 18-70 y old, and had mTNBC that had progressed after 1or 2 prior chemotherapy regimens in the metastatic setting. NVBOX was given biweekly every 4 week for a maximum of 6 cycles. The primary endpoint was progression-free survival (PFS). Forty-4 patients were recruited. All patients had been exposed to anthracyclines and/or taxanes; 56.8% of patients were cis/carbo-platin pretreated. Among the 38 evaluable patients, overall response rate was 31.6% and 7 lasted ≥ 6 months. The median PFS and overall survival (OS) were 4.3 (95% CI, 3.6-5.0) months and 12.6 (95% CI, 8.1-17.0) months, respectively. PFS and OS was significantly shorter in patients with interval from diagnosis to recurrence ≤ 1 y and time to progression (TTP) of 1-2 previous regimens before recruitment ≤ 3 months. For 34 patients who were treated in second line setting, prior platinum was a factor significantly compromising the PFS of NVBOX. Grade 3/4 hematologic toxicities included neutropenia (70.5%), thrombocytopenia (27.3%) and anemia (15.9%). The most frequent grade 3/4 non-hematologic toxicities were constipation/abdominal distension (20.5%) and nausea/vomiting (13.6%). We conclude that biweekly NVBOX regimen is effective with a good safety profile in the second- or third-line mTNBC, which warrants further investigation in a phase III study. This trial was registered with www.clinicaltrials.gov (no. NCT01528826).
authors: a Department of Medical Oncology ; Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University ; Shanghai , China.
authors: Jian
authors: J
authors: Zhang
authors: Leiping
authors: L
authors: Wang
authors: Zhonghua
authors: Z
authors: Wang
authors: Xichun
authors: X
authors: Hu
authors: Biyun
authors: B
authors: Wang
authors: Jun
authors: J
authors: Cao
authors: Fangfang
authors: F
authors: Lv
authors: Chunlei
authors: C
authors: Zhen
authors: Sheng
authors: S
authors: Zhang
authors: Zhimin
authors: Z
authors: Shao
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D019233:Retreatment; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D014747:Vinblastine; D000077235:Vinorelbine
keywords: AE, adverse events; ANC, absolute neutrophil count; CBR, rate of clinical benefit; CI, confidence interval; CR, complete response; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IHC, immunohistochemistry; IV, intravenously; MBC, metastatic breast cancer; ORR, overall response rate; PR, partial response; PgR, progesterone receptor; SD, stable disease; TNBC, triple-negative breast cancer; TTP, time to progression; ULN, upper limit of normal; chemotherapy; mTNBC, metastatic triple-negative breast cancer; metastatic breast cancer; oxaliplatin; triple-negative; vinorelbine
references: Ann Oncol. 1998 Oct;9(10):1053-71
references: 9834817
references: Genes Chromosomes Cancer. 2006 Nov;45(11):1033-40
references: 16897746
references: Clin Breast Cancer. 2009 Feb;9(1):29-33
references: 19299237
references: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
references: 17671126
references: Br J Cancer. 1989 Apr;59(4):527-34
references: 2653399
references: Breast Cancer Res Treat. 2009 May;115(2):423-8
references: 18543098
references: Clin Cancer Res. 2009 Jan 15;15(2):441-51
references: 19147748
references: J Clin Oncol. 2001 Jan 15;19(2):458-63
references: 11208839
references: J Clin Oncol. 2002 May 15;20(10):2551-8
references: 12011135
references: Lancet Oncol. 2007 Mar;8(3):219-25
references: 17329192
references: Int J Cancer. 1991 May 10;48(2):265-9
references: 2019469
references: Ann Oncol. 2011 Apr;22(4):848-856
references: 20924076
references: Breast Cancer Res Treat. 2012 Jun;133(3):1067-75
references: 22415477
references: J Clin Oncol. 2012 Jul 20;30(21):2615-23
references: 22665533
references: Biochem Pharmacol. 1996 Dec 24;52(12):1855-65
references: 8951344
references: Anticancer Drugs. 2006 Mar;17(3):337-43
references: 16520663
references: Lung Cancer. 2005 Feb;47(2):277-81
references: 15639727
references: Histopathology. 2008 Jan;52(1):108-18
references: 18171422
references: J Clin Oncol. 1993 Jul;11(7):1245-52
references: 8315421
references: Nature. 2000 Aug 17;406(6797):747-52
references: 10963602
references: Ann Oncol. 2013 May;24(5):1219-25
references: 23223332
references: Anticancer Drugs. 2009 Feb;20(2):105-8
references: 19209026
references: Ann Oncol. 2002 Jan;13(1):103-7
references: 11863089
references: N Engl J Med. 2010 Nov 11;363(20):1938-48
references: 21067385
references: Clin Cancer Res. 2008 Dec 15;14(24):8010-8
references: 19088017
references: N Engl J Med. 2011 Jan 20;364(3):205-14
references: 21208101
references: Ann Oncol. 1994 Nov;5(9):854-7
references: 7848890
references: Anticancer Drugs. 2011 Mar;22(3):283-9
references: 21150776
references: Semin Oncol. 1998 Apr;25(2 Suppl 5):4-12
references: 9609103
references: Cancer Invest. 2003;21(4):497-504
references: 14533438
references: Anticancer Res. 2011 May;31(5):1765-7
references: 21617237
references: Breast Cancer Res Treat. 2013 Jan;137(2):483-92
references: 23242585
references: J Clin Oncol. 2013 Jul 10;31(20):2586-92
references: 23733761
references: J Clin Oncol. 2011 Mar 10;29(8):1007-13
references: 21205758